Wedbush is removing Ascendis Pharma (ASND) and MoonLake Immunotherapeutics (MLTX) from the firm’s Best Ideas List due to analyst departure. The firm has Outperform ratings on both names.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ASND:
- Ascendis Pharma price target raised to $260 from $196 at Wells Fargo
- Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
- Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
- Ascendis Pharma price target raised to $225 from $207 at Wedbush
- Ascendis Pharma price target raised to $182 from $146 at Citi
